Skip to main content
BioNTech SE logo

BioNTech SE — Investor Relations & Filings

Ticker · BNTX ISIN · US09075V1026 LEI · 894500UZJ5LG1F8J1U58 US Manufacturing
Filings indexed 522 across all filing types
Latest filing 2026-04-13 Foreign Filer Report
Country DE Germany
Listing US BNTX

About BioNTech SE

https://www.biontech.com/

BioNTech SE is a global biotechnology company pioneering novel therapies for cancer and infectious diseases. The company leverages its deep expertise in immunology to develop a diverse portfolio of therapeutic platforms. Its oncology pipeline includes mRNA-based cancer immunotherapies, next-generation immunomodulators, and targeted therapies, with a strategy focused on creating synergistic combinations. In infectious diseases, BioNTech applies its proprietary mRNA technology to develop vaccines, most notably co-developing the first authorized mRNA-based vaccine for COVID-19. The company's core mission is to translate scientific research into innovative treatments that harness the power of the immune system to improve or establish new standards of care for patients globally.

Recent filings

Filing Released Lang Actions
6-K - BioNTech SE (0001776985) (Filer)
Foreign Filer Report
2026-04-13 English
3 - BioNTech SE (0001776985) (Issuer)
Director's Dealing
2026-03-25 English
3 - BioNTech SE (0001776985) (Issuer)
Director's Dealing
2026-03-25 English
3 - BioNTech SE (0001776985) (Issuer)
Director's Dealing
2026-03-25 English
3 - BioNTech SE (0001776985) (Issuer)
Director's Dealing
2026-03-25 English
3 - BioNTech SE (0001776985) (Issuer)
Director's Dealing
2026-03-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.